Skip to search formSkip to main contentSkip to account menu

denileukin diftitox

Known as: Diphtheria toxin precursor, NAD(+--diphthamide ADP- ribosyltransferase), Interleukin-2 Fusion Protein 
A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of… 
National Institutes of Health

Related topics

Related topics

9 relations
2 ML denileukin diftitox 0.15 MG/ML InjectionNCIt Antineoplastic Agent Terminologydenileukin diftitox/dexamethasone

Broader (5)

Antineoplastic AgentsDENILEUKINDiphtheria ToxinInterleukin-2

Narrower (1)

DAB(389)-interleukin 2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Cancer Therapy : Clinical Frequency of Circulating Tregs with Demethylated FOXP 3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents
Purpose: Regulatory T cells (Tregs) are thought to inhibit antitumor immune responses, and their depletion could therefore have a… 
2010
2010
Correlates of capillary leak syndrome (CLS) in patients with cutaneous T-cell lymphoma (CTCL) during treatment with denileukin diftitox (DD) in a placebo (PBO)-controlled phase III trial.
e18509 Background: Interleukin-2 therapy is associated with capillary leakage which manifests as hypoalbuminemia, hypotension… 
2010
2010
Rate of infection and immunosuppression in two phase III studies of denileukin diftitox (DD) in cutaneous T-cell lymphoma (CTCL).
e18515 Background: CTCL patients are at increased risk for infection because of the disruption of the skin barrier and… 
2010
2010
Duration of response in three phase III studies of denileukin diftitox in cutaneous T-cell lymphoma (CTCL).
8055 Background: Although responses to systemic chemotherapy or electron beam radiation in CTCL patients can be relatively high… 
2006
2006
A phase II trial of denileukin diftitox to treat refractory advanced-stage ovarian cancer.
2506 Background: Denileukin diftitox is a fusion toxin consisting of interleukin-2 genetically fused to diphtheria toxin. It is… 
2004
2004
Rapid Purification of a New Humanized Single-chain Fv Antibody／Human Interleukin-2 Fusion Protein Reactive against HER2 Receptor
Human embryonic kidney 293 cells were transfected with plasmid pcDNA-H520C9scFv-rhlL-2 containing a chimeric cDNA encoding the… 
2003
2003
Standard- und experimentelle Therapie kutaner T-Zell-Lymphome
ZusammenfassungKutane T-Zell-Lymphome umfassen eine Gruppe von Krankheiten mit dem Merkmal einer Invasion von monoklonalen T… 
2003
2003
High efficient expression of a humanized single-chain Fv antibody/human interleukin-2 fusion protein directed against p185 in 293 cell line
Objective To express a bispecific humanized single-chain Fv antibody/human IL-2 fusion protein against p185 in 293 cell line and… 
Review
2002
Review
2002
Gateways to Clinical Trials. June 2002.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
1997
1997
Therapy for psoriatic arthritis: sometimes a conflict for psoriasis.
P is one of the commonest, chronic dermatoses and affects 02% of the UK population [1]. The cutaneous manifestations of…